Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GSK to Directly Compare Pazopanib with Sunitinib in RCC
January 5, 2009
- AZ, BMS to Jointly Commercialize Dapagliflozin in Japan
December 22, 2008
- 7 Organizations Call For Further Discussions on Online Sales of Drugs
December 22, 2008
- Sales of Cytotoxic Chemotherapeutics to Peak at US$16.5 Bil. in 2013
December 22, 2008
- Regulatory Reform Council to Not Include Online Sales of Drugs in Its Recommendation
December 22, 2008
- BUSINESS NEWS IN BRIEF
December 22, 2008
- Crestor Reduces CV Risk in Patients with High High-Sensitive CRP Levels: JUPITER Study
December 22, 2008
- New Fees Related to Generics Claimed by Only a Few Pharmacies
December 22, 2008
- Control of Postprandial Hyperglycemia Important to Prevent CV Events: Prof. Tajima
December 22, 2008
- Most Women Have Not Been Examined for Breast Cancer Despite Willingness
December 22, 2008
- High % of ED Patients with Underlying Conditions Satisfied with Levitra: Bayer Schering
December 22, 2008
- Nichi-Iko Merges 3 Subsidiaries
December 22, 2008
- GLP-1 Analogues, DPP-4 Inhibitors to Cut Treatment Cost for Diabetes: Dr Kobayashi
December 22, 2008
- Daiichi Sankyo Applies for Olmesartan + Ca Blocker Combination
December 22, 2008
- Relenza Should Be More Effectively Used in Combination with Tamiflu: Prof. Matsumoto
December 22, 2008
- DB of Medical Bills to Help Drug Risk Assessment
December 22, 2008
- Prescription of Tamiflu by Phone to Be Permitted upon Onset of Pandemic of New-Type Flu
December 22, 2008
- Aspirin Should Be Reimbursed at Low Doses to Prevent Arteriosclerotic Diseases
December 22, 2008
- Janssen Offers Opportunities to Experience Virtual AD/HD
December 22, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 22, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…